Dr. Alexander "Sandro" Sulakvelidze, Ph.D., is the President and CEO of Intralytix, Inc. Dr. Sulakvelidze is an internationally recognized expert in phage technology. He has published extensively about phage biocontrol and phage therapy and has pioneered the approach of using bacteriophages for modulating human microbiome. Dr. Sulakvelidze served as founding Editor-in-Chief of the journal Bacteriophage. He also co-edited a major book about bacteriophages called "Bacteriophages: Biology and Applications," which was published by the CRC Press. Dr. Sulakvelidze serves on numerous review panels for various scientific journals and funding agencies, and he is also the author of several issued and pending patents in the field of bacteriophages. Since the inception of the Company, Dr. Sulakvelidze has been leading all product development and commercialization efforts and he has been directly responsible for shaping up all operational priorities.